ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual London Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Nov 4, 2020--
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Virtual London Healthcare Conference. The presentation is scheduled for November 18, 2020 at 12:00pm ET.
A webcast of the presentation will be accessible through the Investors and Media section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.
ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20201104005579/en/
CONTACT: INVESTOR RELATIONS AND MEDIA
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: ONCOLOGY PROFESSIONAL SERVICES HEALTH FINANCE PHARMACEUTICAL BANKING BIOTECHNOLOGY
SOURCE: ImmunoGen, Inc.
Copyright Business Wire 2020.
PUB: 11/04/2020 04:30 PM/DISC: 11/04/2020 04:31 PM